EMA Authorised: Rozlytrek (Entrectinib) — Roche Registration GmbH

View source ↗

Summary

The EMA authorises Rozlytrek (entrectinib) for cancer, including non-small cell lung carcinoma, under conditional approval.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Non-small Cell Lung Carcinoma

Drugs mentioned

• Rozlytrek (entrectinib)

Snippet

Status: Authorised. Therapeutic area: Cancer;Carcinoma, Non-Small-Cell Lung. MAH: Roche Registration GmbH. Decision date: 24/03/2025. Conditional approval